MCL1

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

Retrieved on: 
Wednesday, March 9, 2022
MCL1, Drug, Private Securities Litigation Reform Act, Company, Research, U.S. Securities and Exchange Commission, CDK9, Cancer, BTK, Bevacizumab, Acalabrutinib, Internal medicine, PRMT5, Woman, Forward-looking statement, Trastuzumab emtansine, Genentech, Risk, Leadership, BRM, Brain, GLOBE, Patient, News, BeiGene, Security (finance), COVID-19, Pharmacology, Venetoclax, Therapy, Rituximab, Stanford University, Goal, Biotechnology, Tislelizumab, Pharmaceutical industry, Prelude, Hematology

WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announcedthat Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022.

Key Points: 
  • WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announcedthat Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022.
  • Dr. Huang is currently Chief Medical Officer, Hematology, at BeiGene, Ltd., a global, science-driven biotechnology company developing oral small molecules and monoclonal antibodies for cancer.
  • Janes deep experience in oncology drug development and her strategic leadership throughout the lifecycle of multiple products resulting in successful global regulatory approvals will be of great value to Prelude, stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Safety, BCL2, AACR, MCL1, Initiate, Completeness, Prelude, Company, IND, CDK9, Survival, SMARCA4, SMARCA2, Cancer, Protein, IV, Breast, CNS, PRMT5, IDH1, SWI, Brain, GLOBE, BRM, Patient, Breast cancer, Uveal melanoma, American Association, Central nervous system, BRG1, CDK6, GBM, Association, Program, Glioblastoma, American Association for Cancer Research, Pharmaceutical industry, Medical imaging, Vaccine

Through disciplined and effective execution, Prelude made meaningful progress across all of our portfolio programs in 2021, said Kris Vaddi, Ph.D., Chief Executive Officer.

Key Points: 
  • Through disciplined and effective execution, Prelude made meaningful progress across all of our portfolio programs in 2021, said Kris Vaddi, Ph.D., Chief Executive Officer.
  • Because of these efforts, we now have five distinct precision oncology programs with four internally discovered molecules in clinical development.
  • One of our key objectives in 2022 is to focus our development efforts and generate the clinical data necessary to prioritize these programs.
  • Prelude has identified a number of highly selective SMARCA2 degraders that have the potential to be first-in-class for SMARCA4-deleted cancers.

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Friday, February 11, 2022
NASDAQ, CNS, Patient, PRMT5, CDK9, Doctor of Philosophy, SMARCA2, MCL1, Therapy, Cancer, Conference, GLOBE, Pharmaceutical industry

WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m.

Key Points: 
  • WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18 at 1:40 p.m.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis.
  • PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors.
  • In addition, the Companys pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Tuesday, January 4, 2022
CNS, PRMT5, Doctor of Philosophy, GLOBE, SMARCA2, Conference, ET, CDK9, Therapy, Patient, MCL1, Cancer, Pharmaceutical industry

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022.

Key Points: 
  • WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13, 2022.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis.
  • PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors.
  • In addition, the Companys pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

MRA Group Signs First Long-Term Lease at Chestnut Run Innovation & Science Park in Wilmington, Delaware

Retrieved on: 
Tuesday, December 21, 2021
St. Mary Medical Center, New Castle County, Delaware, Doctor of Philosophy, Veteran, University of Pennsylvania, Patient, SMARCA2, Cancer, DE, D, News, CEO, CNS, CDK9, Bop TV, Growth, University, Foodservice, Acquisition, View, Restaurant, Chestnut Run Farm, ST, Solution, MCL1, MRA, DuPont, Company, Laboratory, Therapy, Research, Multimedia, CRISP, PRMT5, Management, Pharmaceutical industry

WILMINGTON, Del., Dec. 21, 2021 /PRNewswire/ -- MRA Group (MRA) announced today that on November 30, 2021 it signed the first long-term lease for research and laboratory facilities at Chestnut Run Innovation & Science Park (CRISP), MRA's recently announced life science and manufacturing campus in Wilmington, DE.

Key Points: 
  • WILMINGTON, Del., Dec. 21, 2021 /PRNewswire/ -- MRA Group (MRA) announced today that on November 30, 2021 it signed the first long-term lease for research and laboratory facilities at Chestnut Run Innovation & Science Park (CRISP), MRA's recently announced life science and manufacturing campus in Wilmington, DE.
  • "MRA's acquisition of a significant portion of the Chestnut Run property is great news for Delaware and the state's role in an ever-expanding life sciences sector," said Kurt Foreman, President & CEO of Delaware Prosperity Partnership.
  • We thank the State of Delaware for its ongoing investment in building an entrepreneurial and connected business community."
  • We look forward to continuing to partner with the MRA Group to ensure CRISP flourishes as a thriving hub of scientific investment."

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 11, 2021
Forward-looking statement, Cancer, Failure, KOL, DHL, RNA, MYC, Poster, Clinical trial, Drug Quality and Security Act, RNA polymerase II, Securities Exchange Act of 1934, Eastern Time Zone, Translational medicine, Nasdaq, Biomarker, Immortalised cell line, 8-K, Form 10-K, COVID-19, Securities Act of 1933, Survival, Ohio State University, Lists of people executed in the United States, University of Cincinnati, Neoplasm, Patient, Disease, Therapy, DLBCL, BTK, University, GLOBE, ASH, Chronic lymphocytic leukemia, Blood, Apoptosis, CDK9, EST, MCL1, Q&A, Society, Pharmaceutical industry, Fine chemical, Vaccine, Risk management, Bayer, CLL

PALO ALTO, Calif., Dec. 11, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced data on VIP152, the Company’s PTEFb/CDK9 inhibitor, in high-grade B-cell lymphoma (HGBL), formerly referred to as double-hit lymphoma (DHL), and chronic lymphocytic leukemia (CLL), in two presentations at the 63rd American Society of Hematology (ASH) Annual Meeting held December 11-14, 2021 in Atlanta GA.

Key Points: 
  • The pharmacodynamic effect demonstrated in the blood of HGBL patients treated with VIP152 suggests that the effect may translate to the clinic.
  • VIP152 is currently being evaluated in HGBL patients and other MYC expressing indications in the clinic (ClinicalTrials.gov Identifier: NCT02635672).
  • VIP152 induces apoptosis in CLL cell lines and demonstrates cytotoxic activity that overcomes stromal protection of primary CLL samples.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 23, 2021
Patient, Cancer, Conference, MCL1, PRMT5, Doctor of Philosophy, GLOBE, SMARCA2, CDK9, Therapy, CNS, Pharmaceutical industry

WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place on Wednesday, December 1, 2021 at 9:15 am ET.

Key Points: 
  • WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place on Wednesday, December 1, 2021 at 9:15 am ET.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative, potential best-in-class molecules targeting critical cancer cell pathways involved in cancer pathogenesis.
  • PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors.
  • In addition, the Companys pipeline includes PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Retrieved on: 
Monday, November 8, 2021
Safety, Sarcoma, Lymphatic system, MCL1, Cancer, Private Securities Litigation Reform Act, Therapy, Prostate cancer, PRMT5, Security (finance), Doctor of Philosophy, Goal, COVID-19, Forward-looking statement, AACR, CNS, Conference, Biotechnology, Company, U.S. Securities and Exchange Commission, GLOBE, Breast cancer, CDK9, MYC, Investigational New Drug, SMARCA2, Apoptosis, Patient, FDA, IND, Pharmaceutical industry, Medical imaging

In preclinical studies, PRT2527 was shown to reduce MCL1 and MYC protein levels and was highly active in preclinical models at well-tolerated doses.

Key Points: 
  • In preclinical studies, PRT2527 was shown to reduce MCL1 and MYC protein levels and was highly active in preclinical models at well-tolerated doses.
  • PRT2527 has demonstrated high potency and kinase selectivity which may offer improved efficacy and safety compared to less selective CDK9 inhibitors.
  • PRT1419, a potent and selective MCL1 inhibitor, is in Phase 1 development for patients with relapsed/refractory hematologic malignancies and solid tumors.
  • The Companys pipeline also includes PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader, PRT-K4, a highly selective kinase inhibitor, and additional discovery stage programs.

Vincerx Pharma Announces Presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
2021 Essex County Council election, MYC, Cancer, PALO, Patient, Abstract, ASH, Drug resistance, CDK9, MCL1, Program, Nasdaq, Therapy, GLOBE, Society, Fine chemical

PALO ALTO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.(Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announcedthat two abstracts related to the Companys selective PTEFb/CDK9 inhibitor, VIP152, program have been accepted for presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, to be held December 11-14, 2021 in Atlanta, GA.

Key Points: 
  • PALO ALTO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.(Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announcedthat two abstracts related to the Companys selective PTEFb/CDK9 inhibitor, VIP152, program have been accepted for presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, to be held December 11-14, 2021 in Atlanta, GA.
  • The following abstracts were published today and are now available on the ASH website at www.hematology.org .
  • VIP152, a selective CDK9 inhibitor, induces complete regression of high-grade B-cell lymphoma (HGBL) models and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule.
  • (Abstract #1192)
    Molecular PharmacologyandDrug Resistance: Lymphoid Neoplasms

DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates

Retrieved on: 
Tuesday, October 12, 2021
Private Securities Litigation Reform Act, Company, Forward-looking statement, Brain, Therapy, SMARCA2, Algorithm, Columbia University, Doctor of Philosophy, MCL1, Department, PRMT5, Drug discovery, Biotechnology, COVID-19, Biology, Protein, Goal, British Journal of Haematology, Drug development, GBM, Cancer, Drug combination, CDK9, Glioblastoma, MD, U.S. Securities and Exchange Commission, Security (finance), CEO, BEST, Solution, VIPER, Biomarker, Neoplasm, Overalls, Patient, Multiple myeloma, Technology, Risk, DLBCL, Systems biology, Medical imaging, Pharmaceutical industry, Fine chemical

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics.

Key Points: 
  • NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics.
  • Additionally, the collaboration will mechanistically characterize potential therapeutic opportunities for Prelude's pipeline molecules targeting various oncogenic pathways across multiple hematologic malignancies and solid tumor subtypes, as selected by Prelude Therapeutics.
  • As part of the BEST initiative, DarwinHealth will provide a comprehensive readout of the potential clinical value of select Prelude pipeline moleculesacross a spectrum of tumor types.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.